Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 7/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24869748 | 0.80 | MAOA (0.41) | WDR5ALDH1A1KMT2ATDP1 | |
| SCHEMBL24869753 | 0.79 | MAOB (0.41) | WDR5ALDH1A1KMT2ATDP1 | |
| SCHEMBL30875088 | 0.79 | MAOB (0.41) | WDR5ALDH1A1KMT2ATDP1 | |
| SCHEMBL24869743 | 0.79 | MALT1 (0.44) | WDR5ALDH1A1KMT2ATDP1MALT1 | |
| SCHEMBL24869355 | 0.78 | NPC1 (0.49) | MALT1AXL | |
| SCHEMBL24869524 | 0.78 | MALT1 (0.51) | ALDH1A1MALT1 | |
| SCHEMBL24869518 | 0.78 | MALT1 (0.47) | ALDH1A1KMT2AMALT1 | |
| SCHEMBL24869354 | 0.77 | NPC1 (0.40) | ALDH1A1KMT2ATDP1MALT1 | |
| SCHEMBL24869525 | 0.75 | MALT1 (0.53) | MALT1 | |
| SCHEMBL24869352 | 0.75 | GRM4 (0.47) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4368618-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2024-05-15 | — | — | EP | claimed |
| CN-117715898-A | Six-membered aryl or heteroaryl amide compound, composition and application thereof | 贝达药业股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | claimed |
| US-20240336594-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2024-10-10 | — | — | US | disclosed |
| CN-117715898-A | Six-membered aryl or heteroaryl amide compound, composition and application thereof | 贝达药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336594-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | MALT1, CYP51A1, BCR | IKBKE 230/4885TBK1 767/4885FGFR1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.